Ovarian cancer is the sixth most common cancer and the seventh most common cause of cancer deaths in women.1 Currently, chemotherapy based on platinum drugs (carboplatin or cisplatin) in combination with paclitaxel is a standard treatment for patients with ovarian cancer,2 because platinum drugs and paclitaxel trigger different apoptosis signaling pathways in ovarian cancer cells.3–5 Moreover, platinum drugs trigger cell apoptosis by crosslinking DNA,6 whereas paclitaxel does so by inducing cell cycle arrest at the G2/M phase via binding to the beta-tubulin subunit of microtubules. This evidence concerns the gene TUBB and ovarian cancer.